Nordic Nanovector (OB:NANOV) - Cotización, noticias y análisis

Resumen de acción NANOV

Nordic Nanovector ASA, a biopharmaceutical company, develops therapeutics for hematological cancers in Norway.

NANOV fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Recompensas

Análisis de riesgos

Los beneficios han disminuido un 4.6% al año en los últimos 5 años

Tiene unos ingresos inferiores a 1 millón de dólares (NOK0)

Alta volatilidad del precio de la acción en los últimos 3 meses

Tiene menos de 1 año de cash runway

+ 1 riesgos adicionales

Competidores de Nordic Nanovector ASA

Thor Medical

OB:TRMED

kr249.0m

Lytix Biopharma

OB:LYTIX

kr220.4m

Arctic Bioscience

OB:ABS

kr252.4m

Norda

OTCNO:NORD

kr203.8m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Nordic Nanovector
Historical stock prices
Current Share Price	kr2.00
52 Week High	kr3.34
52 Week Low	kr0.65
Beta	1.61
1 Month Change	167.11%
3 Month Change	149.44%
1 Year Change	-22.20%
3 Year Change	-90.38%
5 Year Change	-96.64%
Change since IPO	-92.86%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	NANOV	NO Biotechs	Mercado NO
7D	-18.3%	-6.1%	-1.0%
1Y	-22.2%	-74.6%	2.8%

Rentabilidad vs. Industria: NANOV superó al sector Norwegian Biotechs , que obtuvo un rendimiento del -61.9% el año pasado.

Rentabilidad vs. Mercado: NANOV obtuvo unos resultados inferiores a los del mercado Norwegian, que fue del -0.1% el año pasado.

Volatilidad de los precios

Is NANOV's price volatile compared to industry and market?
NANOV volatility
NANOV Average Weekly Movement	39.3%
Biotechs Industry Average Movement	10.3%
Market Average Movement	5.1%
10% most volatile stocks in NO Market	10.5%
10% least volatile stocks in NO Market	2.9%

Precio estable de las acciones: NANOVha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: NANOVLa volatilidad semanal ha pasado de 24% a 39% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2009	18	Alf Bjornseth	www.nordicnanovector.com

Resumen de fundamentos de Nordic Nanovector ASA

¿Cómo se comparan los beneficios e ingresos de Nordic Nanovector con su capitalización de mercado?
Estadísticas fundamentales de NANOV
Capitalización bursátil	kr231.84m
Beneficios(TTM)	-kr311.24m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-0.7x

Ratio precio-beneficio (PE)

¿Está NANOV sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de NANOV
Ingresos	kr0
Coste de los ingresos	kr0
Beneficio bruto	kr0
Otros gastos	kr311.24m
Beneficios	-kr311.24m

Últimos beneficios comunicados

Dec 31, 2022

Próxima fecha de beneficios

Aug 31, 2023

Beneficios por acción (BPA)	-2.68
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado NANOV a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción NANOV

Recompensas

Análisis de riesgos

Competidores de Nordic Nanovector ASA

OB:TRMED

kr249.0m

OB:LYTIX

kr220.4m

OB:ABS

kr252.4m

OTCNO:NORD

kr203.8m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Nordic Nanovector ASA Approves the Appointment of Ludvik Sandnes as New Chairman

Nordic Nanovector ASA Announces Resignation of Jostein Dahle, Chief Scientific Officer and Co-Founder

Chairperson recently bought kr436k worth of stock

New major risk - Share price stability

Nordic Nanovector ASA Announces CFO Changes

Nordic Nanovector ASA Announces Resignation of Eddie Berglund from the Board Effect from January 19, 2023

Recent updates

Nordic Nanovector ASA Approves the Appointment of Ludvik Sandnes as New Chairman

Nordic Nanovector ASA Announces Resignation of Jostein Dahle, Chief Scientific Officer and Co-Founder

Chairperson recently bought kr436k worth of stock

New major risk - Share price stability

Nordic Nanovector ASA Announces CFO Changes

Nordic Nanovector ASA Announces Resignation of Eddie Berglund from the Board Effect from January 19, 2023

No independent directors

Nordic Nanovector ASA Approves Board Changes

Nordic Nanovector ASA to Report First Half, 2023 Results on Aug 31, 2023

Nordic Nanovector ASA (OB:NANOV) agreed to acquire 100% stake in APIM Therapeutics AS from Sarsia Seed AS, Trond Mohn Stiftelsen, Norsk Innovasjonskapital (NIK) III Fund, and Investinor Direkte AS.

Nordic Nanovector ASA Announces Resignation of Solveig Hellebust, Jean Pierre Bizzari and Thomas Ramdahl from the Board

Can Nordic Nanovector (OB:NANOV) Afford To Invest In Growth?

Nordic Nanovector ASA Announces Executive Changes

Nordic Nanovector ASA to Report Q2, 2022 Results on Aug 31, 2022

Nordic Nanovector to Seek Regulatory Feedback Following Its Preliminary Review and Independent Data Evaluation of Paradigme, Its Phase 2B Trial with Betalutin in R/R Follicular Lymphoma

Nordic Nanovector ASA Provides an Update on PARADIGME, Its Phase 2b trial of Betalutin in R/R FL as a Result of Continuing Slow Recruitment

Nordic Nanovector ASA Publishes Highlights Synergistic Potential of CD37-Targeted Radioimmunoconjugate Humalutin

Price target decreased to kr26.00

Price target decreased to kr26.00

Insufficient new directors

Price target increased to kr31.00

Nordic Nanovector ASA Provides an Update on the Timeline for PARADIGME

Is Nordic Nanovector (OB:NANOV) In A Good Position To Invest In Growth?

Price target decreased to kr27.25

Nordic Nanovector ASA Provides Update on Paradigme, Its Phase 2B Pivotal Trial with Betalutin® in R/R Follicular Lymphoma

Chief Executive Officer Peter Braun has left the company

We Think Nordic Nanovector (OB:NANOV) Needs To Drive Business Growth Carefully

Nordic Nanovector Announces Initial Results from LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Nordic Nanovector ASA Announces Update from Archer-1 Phase 1B Trial of Betalutin® in Combination with Rituximab in 2L Follicular Lymphoma

Independent Director has left the company

Nordic Nanovector ASA Appoints Peter L. Braun as Chief Executive Officer, Effective 6 April 2021

Price target raised to kr28.25

Nordic Nanovector ASA Sees Significant Improvement in Patient Recruitment Rate in PARADIGME, its Single-Arm Phase 2 Pivotal Trial with Betalutin in R/R Follicular Lymphoma

New 90-day high: kr20.00

Nordic Nanovector ASA to Report Fiscal Year 2020 Results on Mar 27, 2021

Is Nordic Nanovector (OB:NANOV) In A Good Position To Invest In Growth?

Nordic Nanovector ASA to Report Q2, 2021 Results on Aug 27, 2021

Nordic Nanovector ASA Completes Patient Enrolment into Phase 1 Trial of Betalutin® in Diffuse Large B Cell Lymphoma

Price target lowered to kr21.00

Price target lowered to kr38.50

Nordic Nanovector ASA Completes Enrolment into Second Safety Cohort of Follicular Lymphoma Patients in Archer-1 Phase 1B Betalutin®/Rituximab Combination Trial

New 90-day low: kr14.85

Nordic Nanovector Asa Publishes Results of Preclinical Study Demonstrating Betalutin Reverses Tumour Resistance to Rituximab in NHL Disease Models

New 90-day low: kr16.83

Nordic Nanovector Launches A -2-Haematogical L Cancers

New 90-day high - kr27.90